Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 26489824 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 202 | 26489827 |
US |
27 | 2 |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, |
||||
ERENUMAB-AOOE, |
||||
| 203 | 26489954 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 204 | 26490559 |
US |
||
Skin swelling, Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 205 | 26491267 |
US |
2 | |
Device defective, Device deployment issue, Device delivery system issue, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Device malfunction, |
||||
SECUKINUMAB, |
||||
| 206 | 26480330 |
US |
12 | |
Device malfunction, Wrong technique in product usage process, Exposure via skin contact, Product use issue, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 207 | 26480361 |
US |
||
Device malfunction, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 208 | 26480623 |
US |
71 | 2 |
Exposure via skin contact, Product dose omission issue, Device issue, No adverse event, |
||||
TOCILIZUMAB, VALSARTAN, VALSARTAN ORAL, CELECOXIB, SULFASALAZINE, GABAPENTIN, ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE, ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE, IPRATROPIUM BROMIDE, |
||||
| 209 | 26480746 |
US |
23 | |
Drug delivery system malfunction, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Wrong technique in device usage process, |
||||
INFLIXIMAB-DYYB, LEVONORGESTREL, |
||||
| 210 | 26481023 |
US |
45 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
| 211 | 26481582 |
US |
77 | 1 |
Injection site discolouration, Accidental exposure to product, Exposure via skin contact, Product communication issue, Device use error, |
||||
EVOLOCUMAB, |
||||
| 212 | 26481917 |
US |
18 | |
Injection site pain, Device issue, Device defective, Incorrect dose administered by device, Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Product use issue, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 213 | 26481921 |
US |
23 | |
Device malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
INFLIXIMAB-DYYB, |
||||
| 214 | 26481925 |
US |
59 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 215 | 26482011 |
US |
2 | |
Wheezing, Dyspnoea, Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 216 | 26482221 |
US |
47 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 217 | 26482494 |
US |
95 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 218 | 26482708 |
US |
||
Necrosis, Infusion site extravasation, Accidental exposure to product, Exposure via skin contact, |
||||
AVALGLUCOSIDASE ALFA-NGPT, AVALGLUCOSIDASE ALFA-NGPT, |
||||
| 219 | 26482735 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 220 | 26482741 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 221 | 26482890 |
US |
21 | |
Wrong technique in product usage process, Exposure via skin contact, Accidental exposure to product, |
||||
INFLIXIMAB-DYYB, |
||||
| 222 | 26482963 |
US |
56 | |
Wrong technique in product usage process, Product dose omission issue, Exposure via skin contact, Accidental exposure to product, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 223 | 26482967 |
US |
||
Device malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
INFLIXIMAB-DYYB, |
||||
| 224 | 26482989 |
US |
24 | |
Injection site haemorrhage, Drug delivery system malfunction, Wrong technique in product usage process, Drug dose omission by device, Accidental exposure to product, Exposure via eye contact, Exposure via skin contact, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, SERTRALINE, |
||||
| 225 | 26483041 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, Extra dose administered, |
||||
DUPILUMAB, ALBUTEROL SULFATE, PREDNISONE, ALBUTEROL SULFATE AND BUDESONIDE, MONTELUKAST SODIUM, MONTELUKAST, |
||||
| 226 | 26483093 |
US |
||
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 227 | 26483108 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 228 | 26483404 |
US |
83 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 229 | 26483471 |
US |
55 | |
Device malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 230 | 26484394 |
US |
30 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 231 | 26484396 |
US |
69 | 2 |
Accidental exposure to product, Incorrect dose administered by device, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 232 | 26484404 |
US |
23 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 233 | 26484473 |
US |
61 | 2 |
Device delivery system issue, Exposure via skin contact, Accidental exposure to product, |
||||
ABATACEPT, ABATACEPT, |
||||
| 234 | 26484567 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 235 | 26485117 |
US |
11 | |
Drug delivery system malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB, |
||||
| 236 | 26485180 |
US |
42 | |
Device leakage, Exposure via skin contact, Accidental exposure to product, |
||||
INFLIXIMAB-DYYB, |
||||
| 237 | 26485212 |
US |
66 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 238 | 26485215 |
US |
62 | |
Drug delivery system malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
INFLIXIMAB-DYYB, |
||||
| 239 | 26485253 |
US |
18 | |
Device malfunction, Abdominal discomfort, Malaise, Pyrexia, Accidental exposure to product, Exposure via skin contact, Product dose omission in error, Wrong technique in product usage process, |
||||
INFLIXIMAB-DYYB, |
||||
| 240 | 26476101 |
US |
63 | 1 |
Ill-defined disorder, Device difficult to use, Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, Product communication issue, |
||||
EVOLOCUMAB, DULAGLUTIDE, |
||||
| 241 | 26476137 |
US |
82 | |
Device malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, DULAGLUTIDE, |
||||
| 242 | 26476250 |
US |
74 | |
Injection site pain, Device malfunction, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 243 | 26476277 |
US |
60 | |
Accidental exposure to product, Exposure via skin contact, Wrong technique in device usage process, Product dose omission in error, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, PREDNISONE, |
||||
| 244 | 26476299 |
US |
60 | |
Device malfunction, Drug dose omission by device, Exposure via skin contact, Accidental exposure to product, Product use issue, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 245 | 26476320 |
US |
75 | |
Drug dose omission by device, Device malfunction, Exposure via skin contact, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 246 | 26476349 |
US |
19 | |
Device mechanical issue, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 247 | 26476369 |
US |
||
Device malfunction, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 248 | 26476398 |
US |
67 | |
Device malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 249 | 26476404 |
US |
1 | |
Injection site pain, Device difficult to use, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, |
||||
EVOLOCUMAB, TIRZEPATIDE, |
||||
| 250 | 26476498 |
US |
61 | |
Arthritis, Device malfunction, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 251 | 26476622 |
US |
41 | |
Device malfunction, Exposure via skin contact, Accidental exposure to product, Wrong technique in product usage process, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 252 | 26476643 |
US |
35 | |
Device malfunction, Drug dose omission by device, Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 253 | 26476890 |
US |
27 | |
Needle issue, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 254 | 26476947 |
US |
59 | 2 |
Device delivery system issue, Device failure, Exposure via skin contact, Inability to afford medication, |
||||
ABATACEPT, SUCRALFATE, LOSARTAN POTASSIUM, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, FOLIC ACID, GABAPENTIN, LEFLUNOMIDE, ARMODAFINIL, PROGESTERONE, LEVOCETIRIZINE DIHYDROCHLORIDE, |
||||
| 255 | 26477080 |
CA |
51 | |
Device malfunction, Exposure via skin contact, Accidental exposure to product, Drug dose omission by device, Intentional product use issue, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 256 | 26477129 |
US |
16 | |
Device malfunction, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 257 | 26477165 |
US |
2 | |
Psoriatic arthropathy, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Device delivery system issue, |
||||
SECUKINUMAB, SECUKINUMAB, |
||||
| 258 | 26477597 |
US |
76 | 1 |
Device use error, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 259 | 26477744 |
US |
70 | 2 |
Device difficult to use, Accidental exposure to product, Drug dose omission by device, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 260 | 26477975 |
US |
2 | |
Product residue present, Exposure via skin contact, Accidental exposure to product, |
||||
| 261 | 26478268 |
US |
40 | |
Accidental exposure to product, Exposure via skin contact, Device malfunction, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 262 | 26478335 |
US |
1 | |
Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 263 | 26478662 |
US |
21 | |
Device malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
INFLIXIMAB-DYYB, |
||||
| 264 | 26478750 |
US |
48 | |
Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 265 | 26478754 |
US |
44 | |
Device malfunction, Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, Product dose omission issue, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 266 | 26478848 |
US |
54 | |
Device malfunction, Device leakage, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 267 | 26479025 |
US |
44 | |
Incorrect dose administered by device, Exposure via skin contact, Accidental exposure to product, |
||||
INFLIXIMAB, |
||||
| 268 | 26479028 |
US |
18 | |
Device leakage, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, |
||||
INFLIXIMAB-DYYB, |
||||
| 269 | 26479260 |
GB |
24 | |
Drug delivery system malfunction, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, |
||||
INFLIXIMAB-DYYB, |
||||
| 270 | 26479364 |
US |
||
Skin discolouration, Exposure via skin contact, Accidental exposure to product, |
||||
| 271 | 26479722 |
US |
70 | 2 |
Injection site pain, Exposure via skin contact, Accidental exposure to product, Product administration error, Wrong technique in product usage process, |
||||
EVOLOCUMAB, |
||||
| 272 | 26480131 |
US |
74 | |
Device use issue, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, LOSARTAN, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, PREDNISONE, |
||||
| 273 | 26480141 |
US |
47 | |
Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 274 | 26480148 |
US |
66 | |
Device malfunction, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 275 | 26480177 |
US |
62 | |
Upper limb fracture, Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, Product dose omission in error, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 276 | 26480249 |
US |
66 | |
Device malfunction, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 277 | 26480268 |
US |
84 | |
Incorrect dose administered, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, SIMVASTATIN, EZETIMIBE, GABAPENTIN, PREDNISONE, |
||||
| 278 | 26480274 |
US |
45 | |
Drug delivery system malfunction, Adverse event, Exposure via skin contact, Accidental exposure to product, Wrong technique in product usage process, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 279 | 26471582 |
US |
61 | 2 |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, |
||||
ERENUMAB-AOOE, EVOLOCUMAB, |
||||
| 280 | 26471633 |
US |
76 | 2 |
Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
MEPOLIZUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BACLOFEN, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, MODAFINIL, ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, ROSUVASTATIN, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL, BUDESONIDE, |
||||
| 281 | 26471839 |
US |
55 | 2 |
Accidental exposure to product, Exposure via skin contact, Device difficult to use, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 282 | 26472850 |
US |
59 | 2 |
Product communication issue, Device difficult to use, Device difficult to use, Accidental exposure to product, Exposure via skin contact, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 283 | 26472882 |
US |
37 | 2 |
Injection site pain, Exposure via skin contact, Accidental exposure to product, Wrong technique in device usage process, Underdose, |
||||
BELIMUMAB, |
||||
| 284 | 26472883 |
US |
79 | 2 |
Exposure via skin contact, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 285 | 26473091 |
US |
48 | 2 |
Device difficult to use, Incorrect dose administered by device, Accidental exposure to product, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
| 286 | 26473288 |
US |
54 | 2 |
Exposure via skin contact, Product dose omission issue, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 287 | 26473993 |
US |
1 | |
Exposure via skin contact, Incorrect dose administered by device, Device leakage, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, |
||||
| 288 | 26474434 |
US |
1 | |
Device deployment issue, Device delivery system issue, Product leakage, Accidental exposure to product, Exposure via skin contact, Device malfunction, |
||||
SECUKINUMAB, |
||||
| 289 | 26471091 |
US |
2 | |
Accidental exposure to product, Occupational exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 290 | 26470166 |
US |
79 | 2 |
Poor quality device used, Accidental exposure to product, Exposure via skin contact, Injection site pain, |
||||
EVOLOCUMAB, |
||||
| 291 | 26470261 |
US |
63 | 2 |
Incorrect disposal of product, Accidental exposure to product, Exposure via skin contact, Product communication issue, |
||||
EVOLOCUMAB, |
||||
| 292 | 26470539 |
US |
27 | 2 |
Device use error, Accidental exposure to product, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
| 293 | 26470585 |
US |
49 | 2 |
Accidental exposure to product, Exposure via skin contact, Device use error, Device difficult to use, |
||||
ERENUMAB-AOOE, |
||||
| 294 | 26465711 |
US |
57 | 1 |
Injection site bruising, Injection site pain, Exposure via skin contact, Accidental exposure to product, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 295 | 26465954 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, Device use error, Intercepted product storage error, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 296 | 26465979 |
US |
62 | 1 |
Product dose omission issue, Device delivery system issue, Pain, Product label issue, Exposure via skin contact, Accidental exposure to product, Movement disorder, Asthenia, Muscle rigidity, Malaise, |
||||
ABATACEPT, NIFEDIPINE, |
||||
| 297 | 26466547 |
US |
1 | |
Ocular hyperaemia, Periorbital swelling, Exposure via skin contact, Accidental exposure to product, Therapy interrupted, Product availability issue, |
||||
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE, |
||||
| 298 | 26469507 |
US |
70 | 2 |
Exposure via skin contact, Accidental exposure to product, Device difficult to use, Product communication issue, |
||||
ERENUMAB-AOOE, |
||||
| 299 | 26460631 |
CH |
2 | |
Device malfunction, Exposure via skin contact, |
||||
ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, |
||||
| 300 | 26461150 |
CH |
58 | 2 |
Erythema, Dry skin, Injection site pain, Device malfunction, Exposure via skin contact, |
||||
ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, ROPEGINTERFERON ALFA-2B, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28